Antisense-induced down-regulation of thymidylate synthase and enhanced cytotoxicity of 5-FUdR in 5-FUdR-resistant HeLa cells

British Journal of Pharmacology

Volumn 134, Issue 7, 2001, Pages 1437-1446

  Ferguson, Peter J ^a,b   DeMoor, Janice M ^a   Vincent, Mark D ^a,b   Koropatnick, James ^a,b  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

5 fluorodeoxyuridine; Antisense; Drug resistance; Thymidylate synthase

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; FLOXURIDINE; THYMIDYLATE SYNTHASE;

3' UNTRANSLATED REGION; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG POTENTIATION; GENE OVEREXPRESSION; HELA CELL; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0035206772     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704394     Document Type: Article

References (72)

1. Antisense oligonucleotides: Is the glass half full or half empty?
2. Tumor growth inhibition in vivo and G2/M cell cycle arrest induced by antisense oligodcoxynucleotide targeting thymidylate synthase
3. Sequential methotrexate/5-FU: FdUMP formation and TS inhibition in a transplantable rodent colon adenocarcinoma
4. Evidence that the pathway of transferrin receptor mRNA degradation involves an endonucleolytic cleavage within the 3′ UTR and does not involve poly(A) tail shortening
5. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies
6. A phase I study of bcl-2 antisense G3139 (GENTA) and weekly docetaxel in patients with advanced breast cancer and other solid tumors
7. The role of thymidylate synthase in cellular regulation
8. Identification of in vivo target RNA sequences bound by thymidylate synthase
9. Thymidylate synthase protein and p53 mRNA form an in vivo ribonucleoprotein complex
10. Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase
11. Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon γ
12. Identification of a thymidylate synthase ribonucleoprotein complex in human colon cancer cells
13. Identification of an RNA binding site for human thymidylate synthase
14. Interaction of interferon and 5-fluorouracil in the H630 human colon carcinoma cell line
15. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides
16. Thymidylate synthase - A target enzyme in cancer chemotherapy
17. Inhibition of protein kinase Cα expression in a human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters
18. Inhibition of growth of human tumor cell lines in nude mice by an antisense oligonucleotide inhibitor of protein kinase Cα expression
19. Anti-sense oligonucleotides directed against EGF-related growth factors enhance anti-proliferative effect of conventional anti-tumor drugs in human colon-cancer cells
20. Thymidylate synthase expression: An independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer
21. Antisense downregulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU, and Tomudex in HeLa cells
22. Inconstant association between 27-kDa heat-shock protein (Hsp27) content and doxorubicin resistance in human colon cancer cells. The doxorubicin-protecting effect of Hsp27
23. The nm23-H1 gene as a predictor of sensitivity to chemotherapeutic agents in oesophageal squamous cell carcinoma
24. Flow cytometric analysis of cell-killing actions of 5-fluorouracil in human colorectal cancer cells
25. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: A new agent for clinical study
26. Posttranscriptional regulation of thymidylate synthase gene expression
27. Desensitization and sensitization of cells to fluoropyrimidines with different antisenses directed against thymidylate synthase messenger RNA
28. Regulation of p53 expression by thymidylate synthase
29. Activation of c-jun and c-fos genes in dNTP imbalance cell death induced with 5-fluoro-2′-deoxyuridine in mouse mammary tumor FM3A cell line
30. Role in translation of a triple tandemly repeated sequence in the 5′-untranslated region of human thymidylate synthase mRNA
31. Antisense oligonucleotides to class IIIβ tubulin sensitize drug-resistant cells to Taxol
32. The thymidylate synthase inhibitor, ICI D1694, overcomes translational detainment of the enzyme
33. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression
34. Mechanisms of acquired resistance to thymidylate synthase inhibitors: The role of enzyme stability
35. Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes
36. Modulation of drug resistance by β tubulin in paclitaxel-resistant human lung cancer cell lines
37. Sensitization of multidrug-resistant human leukemia cells with MDR1-targeted antisense and inhibition of drug-mediated MDR1 induction
38. Characterization of a cis-acting regulatory element in the protein coding region of thymidylate synthase mRNA
39. Chemosensitivity of human hepatocellular carcinoma cell line QGY-7703 is related to bcl-2 protein levels
40. Transcription and activity of 5-fluorouracil converting enzymes in fluoropyrimidine resistance in colon cancer in vitro
41. DNA damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells
42. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides
43. Marked variation of thymidylate synthase and folylpolyglutamate synthetase gene expression in human colorectal tumors
44. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide
45. Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells
46. Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer
47. 5-Fluorouracil-mediated thymidylate synthase induction in malignant and nonmalignant human cells
48. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: Implications for treatment with fluorouracil
49. Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed
50. Inhibition of MDR1 gene expression by antimessenger oligonucleotides lowers multiple drug resistance
51. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase
52. A phase I trial of G3139, a bcl2 antisense drug, by continuous infusion (CI) as a single agent and with weekly taxol (T)
53. Effect of 2′-O-methyl antisense ORNs on expression of thymidylate synthase in human colon cancer RKO cells
54. Modified deoxyoligonucleotides stable to exonuclease degradation in serum
55. Detection and quantitation of thymidylate synthase mRNA in human colon adenocarcinoma cell line resistant to 5-fluorouracil by competitive PCR
56. 4PTEGLU assays
57. Antisense oligonucleotides as therapeutic agents - Is the bullet really magical?
58. Physicochemical properties of phosphorothioate oligodeoxynucleotides
59. Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides
60. Enhanced expression of thymidylate synthase may be of prognostic importance in advanced cervical cancer
61. Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer
62. Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method
63. Overcoming multidrug resistance in human tumor cells using free and liposomally encapsulated antisense oligodeoxynucleotides
64. Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors
65. Thymidylate synthase expression in patients with colorectal carcinoma using a polyclonal thymidylate synthase antibody in comparison to the TS 106 monoclonal antibody
66. Thymidylate synthase: A target for combination therapy and determinant of chemotherapeutic response in colorectal cancer
67. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines
68. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy patients with non-Hodgkin's lymphoma
69. Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues
70. Antisense suppression of proline-directed protein kinase FA enhances chemosensitivity in human prostate cancer cells
71. Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex
72. Mechanisms of resistance to fluoropyrimidines